SynthesisHuman vaccines & immunotherapeutics2025
HPV vaccination efficacy in primary and tertiary prevention of vulvar and vaginal HPV-related high grade dysplasia and cancers: A systematic review.
Synthesis in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Knowledge and attitudes of medical students about human papillomavirus (HPV) and HPV vaccine: A cross-sectional survey in Inner Mongolia, China.Human vaccines & immunotherapeutics · 2026Article
- [Vulvar intraepithelial neoplasia and vulvar cancer].Dermatologie (Heidelberg, Germany) · 2026Review
- Adjuvant human papillomavirus vaccination after excisional treatment for cervical precancer.Turkish journal of obstetrics and gynecology · 2026Article
- Early- versus late-onset mortality trends in breast and female genital cancers in Spain, 1999-2024.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Spatio-temporal inequalities in vulvar cancer mortality in Spain, 1999-2023: a nationwide Bayesian analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of HPV vaccination on cervical cancer and condylomas is well-established, but its effectiveness against high grade vulvar and vaginal lesions (VIN/VaIN) and related cancers remains less clear due to their rarity. This systematic review assessed the efficacy of quadrivalent (qHPV) and 9-valent (9vHPV) vaccines in both primary and tertiary prevention of these conditions. Eleven studies met the inclusion criteria. qHPV showed 100% efficacy against HPV16/18-related VIN/VaIN and cancers in per-protocol populations, with reduced but still significant efficacy (71%) in intention-to- treat analyses. The 9vHPV vaccine further reduced risks associated with additional HPV types (31/33/45/52/58). Real-life data revealed decreased incidence of vulvar and vaginal cancers following vaccination, particularly among younger women. While vaccination appeared to reduce recurrence rates after initial treatment of HPV-related lesions, randomized trials have not confirmed a clear adjuvant benefit. Overall, HPV vaccination proves highly effective in preventing vulvar and vaginal disease, especially when administered before HPV exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.